Related Experiment Videos
Levodopa-induced postural hypotension. Treatment with fludrocortisone
Archives of Neurology
|January 1, 1975
Summary
Fludrocortisone acetate effectively treats severe postural hypotension in Parkinson's patients caused by levodopa. This safe treatment improved blood pressure and reduced symptoms without adverse effects.
Area of Science:
- Neurology
- Pharmacology
Background:
- Parkinsonian patients often experience postural hypotension due to levodopa therapy.
- This can necessitate reducing levodopa dosage, compromising Parkinson's symptom control.
Purpose of the Study:
- To evaluate the efficacy and safety of fludrocortisone acetate in treating levodopa-induced postural hypotension in Parkinsonian patients.
Main Methods:
- Six patients with Parkinson's and symptomatic postural hypotension received daily fludrocortisone acetate (0.05-0.2 mg) for 6-10 months.
- Blood pressure and orthostatic symptoms were monitored throughout the treatment period.
Main Results:
- Fludrocortisone acetate satisfactorily alleviated severe orthostatic light-headedness and syncope in all patients.
- Normal supine and upright blood pressures were restored during treatment.
- No adverse reactions were reported.
Conclusions:
- Fludrocortisone acetate is an effective and safe therapeutic option for severe, intractable postural hypotension secondary to levodopa therapy in Parkinsonian patients.
- This treatment allows for optimized levodopa dosages for Parkinson's symptom management.